Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02499835
Recruitment Status : Recruiting
First Posted : July 16, 2015
Last Update Posted : June 5, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-HP plasmid DNA vaccine, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Giving pTVG-HP plasmid DNA vaccine and pembrolizumab may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Hormone-Resistant Prostate Cancer Metastatic Malignant Neoplasm in the Bone Metastatic Malignant Neoplasm in the Soft Tissues Metastatic Prostate Carcinoma Prostate Adenocarcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer Biological: Pembrolizumab Biological: pTVG-HP Plasmid DNA Vaccine Phase 1 Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Once at least 12 subjects per arm are accrued to Arms 1 and 2, and Arm 3 is open to accrual, accrual will occur only to Arm 3 (other arms will be closed). Extended treatment Arm 4 will open only when Arm 3 has met accrual.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Actual Study Start Date : July 1, 2015
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : July 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)
Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
Biological: Pembrolizumab
Given IV
Other Names:
  • 1374853-91-4
  • Immunoglobulin G4
  • Anti-(Human Programmed Cell Death 1)
  • Lambrolizumab
  • Keytruda
  • MK-3475
  • SCH 900475

Biological: pTVG-HP Plasmid DNA Vaccine
Given ID

Experimental: Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)
Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
Biological: Pembrolizumab
Given IV
Other Names:
  • 1374853-91-4
  • Immunoglobulin G4
  • Anti-(Human Programmed Cell Death 1)
  • Lambrolizumab
  • Keytruda
  • MK-3475
  • SCH 900475

Biological: pTVG-HP Plasmid DNA Vaccine
Given ID

Experimental: Extended Treatment Arm III
pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
Biological: Pembrolizumab
Given IV
Other Names:
  • 1374853-91-4
  • Immunoglobulin G4
  • Anti-(Human Programmed Cell Death 1)
  • Lambrolizumab
  • Keytruda
  • MK-3475
  • SCH 900475

Biological: pTVG-HP Plasmid DNA Vaccine
Given ID

Experimental: Extended Treatment Arm IV
pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
Biological: Pembrolizumab
Given IV
Other Names:
  • 1374853-91-4
  • Immunoglobulin G4
  • Anti-(Human Programmed Cell Death 1)
  • Lambrolizumab
  • Keytruda
  • MK-3475
  • SCH 900475

Biological: pTVG-HP Plasmid DNA Vaccine
Given ID




Primary Outcome Measures :
  1. Incidence of adverse events, using the National Cancer Common Terminology Criteria, version 4 [ Time Frame: Up to 12 months after completion of study treatment ]
    Toxicities will be summarized by type and severity in tabular format. Toxicity rates (grade 2, grade 3, grade 4, grade >= 2, grade >= 3, etc.) will be calculated for each study arm and reported along the corresponding 95% confidence intervals. The 95% confidence intervals will be constructed using the Wilson score method. Fisher's exact test will be used to compare toxicity rates between study arms.

  2. Change in serum chemistry parameters [ Time Frame: Baseline to up to 12 months after completion of study treatment ]
    Serum chemistry and amylase parameters will be summarized using standard descriptive statistics. Changes from the baseline assessment will be evaluated using a paired t-test.

  3. 6-month progression free survival rate [ Time Frame: 6 months ]
    6-month progression-free survival rate, along with corresponding two-sided 95% confidence intervals, will be reported for each arm, and for overall combined study. Wilson score method will be used to construct the confidence intervals. Fisher's exact test will be used to compare 6-month progression-free survival rates between study arms. In order to evaluate the 6-month progression-free rate as a function of baseline time point (pretreatment or 3-months post treatment, analysis will be conducted using two different baseline values: date of randomization, and 3-months disease assessment.

  4. Median time to radiographic progression [ Time Frame: Up to 2 years ]
    Median time to radiographic progression will be estimated for each, and for both study arms combined, using Kaplan-Meier method. Log-rank test will be used to perform comparison of time to radiographic progression between study arms. A one-sided 0.10 significance level will be used to conduct the comparison of the 6-month progression-free survival rate and time to radiographic progression between study arms. In order to evaluate the median time to radiographic progression as a function of baseline time point (pretreatment or 3-months post treatment), analysis will be conducted.

  5. Objective response rate [ Time Frame: Up to 2 years ]
    Will be calculated for each study arm and for both arms combined along with the corresponding 95% confidence intervals. The Wilson score method will be used to construct the confidence intervals. Fisher's exact test will be used to compare the objective response and PSA response rates between study arms. Duration of response will be analyzed using the Kaplan-Meier method.

  6. PSA response rate [ Time Frame: Up to 2 years ]
    Will be calculated for each study arm and for both arms combined along with the corresponding 95% confidence intervals. The Wilson score method will be used to construct the confidence intervals. Fisher's exact test will be used to compare the objective response and PSA response rates between study arms. Duration of response will be analyzed using the Kaplan-Meier method.


Secondary Outcome Measures :
  1. PAP-specific immune response [ Time Frame: Up to 2 years ]
    Number and frequencies of PAP-specific immune responses will be summarized in tabular format for each study arm and both study arms combined. A log-linear model will be used to evaluate whether PAP-specific immune response predicts 6-months progression-free survival rate. Interaction between treatment (pembrolizumab administered sequentially versus delayed) and PAP-specific immune response will be included in the model. Analogously, a Cox proportional hazard regression model will be used to examine the association between PAP-specific immune response and time to radiographic progression.

  2. PAP-specific T-cell response [ Time Frame: Up to 2 years ]
    Number and frequencies of PAP-specific T-cell responses will be summarized in tabular format. Fisher's exact test will be used to compare the PAP-specific T-cell response rates between study arms.

  3. PD-1 expression [ Time Frame: Up to day 85 ]
    PD-1 and PD-L1 expression levels will be summarized in terms of means, standard deviations and ranges for each study arm separately and for both arms combined. A linear regression model or a negative binomial regression model will be utilized to evaluate effects of schedule (concurrent versus delayed administration pembrolizumab) on PD-1 expression on number of circulating T cells, and PD-L1 expression on number of circulating epithelial cells. Choice of the model will be dependent on distribution of outcome variables (number of circulating T-cells and number of circulating epithelial cells).

  4. PD-L1 expression [ Time Frame: Up to day 85 ]
    PD-1 and PD-L1 expression levels will be summarized in terms of means, standard deviations and ranges for each study arm separately and for both arms combined. A linear regression model or a negative binomial regression model will be utilized to evaluate effects of schedule (concurrent versus delayed administration pembrolizumab) on PD-1 expression on number of circulating T cells, and PD-L1 expression on number of circulating epithelial cells. Choice of the model will be dependent on distribution of outcome variables (number of circulating T-cells and number of circulating epithelial cells).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
  • Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT of abdomen/pelvis, bone scintigraphy)
  • Castrate-resistant disease, defined as follows:

    • All patients must have received (and be receiving) standard of care androgen deprivation treatment (surgical castration versus gonadotropin-releasing hormone [GnRH] analogue or antagonist treatment); subjects receiving GnRH analogue or antagonist must continue this treatment throughout the time on this study
    • Patients may or may not have been treated previously with a nonsteroidal antiandrogen; for patients previously treated with an antiandrogen, they must be off use of anti-androgen for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration; moreover, subjects who demonstrate an anti-androgen withdrawal response, defined as a >= 25% decline in PSA within 4-6 week of stopping a nonsteroidal antiandrogen, are not eligible until the PSA rises above the nadir observed after antiandrogen withdrawal
    • Patients must have a castrate serum level of testosterone (< 50 ng/dL) within 6 weeks of day 1
  • Progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) bone scan criteria or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during or after completing last therapy:

    • PSA: at least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value >= 2.0 ng/mL
    • Measurable disease: >= 50% increase in the sum of the cross products of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be at least 15 mm by spiral CT to be considered a target lesion
    • Non-measurable (bone) disease: the appearance of two or more new areas of uptake on bone scan (or fluorine F 18 sodium fluoride [NaF] PET/CT) consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or magnetic resonance imaging [MRI])
  • Prior treatment with abiraterone or enzalutamide is permitted, but patients must have been off prior corticosteroid treatment for at least 3 months
  • Life expectancy of at least 6 months
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • White blood cells (WBC) >= 2000/mm^3
  • Absolute neutrophil count (ANC) >= 1000/mm^3
  • Hemoglobin (HgB) >= 9.0 gm/dL
  • Platelets >= 100,000/mm^3
  • Creatinine =< 2.0 mg/dL
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
  • No known history of human immunodeficiency virus (HIV) 1 and 2, human T-lymphotropic virus (HTLV)-1, or active hepatitis B or hepatitis C
  • Patients must be at least 4 weeks from any prior treatments and have recovered (to < grade 2) from acute toxicity attributed to this prior treatment, unless considered chronic
  • Patients must be willing and able (in the opinion of the treating physician) to undergo two research biopsies for the investigational component of this trial
  • Patients must be willing to undergo two leukapheresis procedures for the investigational component of this trial
  • Patients must be willing to undergo FLT PET/CT or NaF PET/CT scans for the investigational component of this trial and have no known allergies to FLT or NaF
  • For those patients who are sexually active, they must be willing to use barrier contraceptive methods during the period of treatment on this trial (and for four weeks after the last DNA immunization treatment for patients in Arm 1)
  • Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written informed consent form indicating such an understanding

Exclusion Criteria:

  • Small cell or other variant (non-adenocarcinoma) prostate cancer histology, unless there is evidence that the tumor expresses PAP
  • Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy
  • Concurrent bisphosphonate therapy is not excluded, however patients should not start bisphosphonate therapy while on this study; those patients already receiving bisphosphonate therapy should continue at the same dosing and schedule as prior to study entry
  • Rapidly progressive symptomatic metastatic disease, as defined by the need for increased opioid analgesics within one month of registration for the treatment of pain attributed to a prostate cancer metastatic lesion; patients receiving opioids must receive approval from the principal investigator (PI) for eligibility
  • Treatment with any of the following medications within 28 days of registration, or while on study, is prohibited:

    • Systemic corticosteroids (at doses over the equivalent of 5 mg prednisone daily) - not permitted within 3 months of registration; inhaled, intranasal or topical corticosteroids are acceptable
    • Prostate cancer (PC)-SPES
    • Saw palmetto
    • Megestrol
    • Ketoconazole
    • 5-alpha-reductase inhibitors - patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study
    • Diethyl stilbestrol
    • Abiraterone
    • Enzalutamide
    • Radium 223 (Xofigo)
    • Any other hormonal agent or supplement being used with the intent of cancer treatment
  • External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
  • Major surgery within 4 weeks of registration is prohibited
  • Prior cytotoxic chemotherapy (for example, but not limited to, docetaxel, mitoxantrone, cabazitaxel) within 6 months of registration is prohibited
  • Patients with a history of life-threatening autoimmune disease
  • Patients with a history of allergic reactions to filgrastim (GM-CSF) or the tetanus vaccine
  • Patients who have undergone splenectomy
  • Patients must not have other active malignancies other than non-melanoma skin cancers or superficial bladder cancer; subjects with a history of other cancers who have been adequately treated and have been recurrence-free for >= 3 years are eligible
  • Patients with known brain metastases
  • Any antibiotic therapy or evidence of infection within 1 week of registration
  • Any other medical intervention or condition, which, in the opinion of the PI or treating physician, could compromise patient safety or adherence with the study requirements (including biopsies or leukapheresis procedures) over the primary 3-6 month treatment period
  • Patients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studies

NOTE: There is no exclusion for prior immune-based therapy. This includes patients previously treated on Arms 1 or 2 who are otherwise eligible for treatment on Arm 3 or 4.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02499835


Contacts
Layout table for location contacts
Contact: Cancer Connect (800) 622-8922 cancerconnect@uwcarbone.wisc.edu

Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin Carbone Cancer Center Recruiting
Madison, Wisconsin, United States, 53792
Contact: Cancer Connect    800-622-8922    cancerconnect@uwcarbone.wisc.edu   
Principal Investigator: Glenn Liu, M.D.         
Sponsors and Collaborators
University of Wisconsin, Madison
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Douglas G McNeel, MD PhD University of Wisconsin, Madison

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT02499835     History of Changes
Other Study ID Numbers: UW15014
2015-0453 ( Other Identifier: IRB )
NCI-2015-01154 ( Registry Identifier: NCI CTRP )
P30CA014520 ( U.S. NIH Grant/Contract )
First Posted: July 16, 2015    Key Record Dates
Last Update Posted: June 5, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Prostatic Neoplasms
Adenocarcinoma
Neoplasms, Second Primary
Bone Neoplasms
Neoplasm Metastasis
Bone Marrow Diseases
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Bone Diseases
Musculoskeletal Diseases
Hematologic Diseases
Neoplastic Processes
Pathologic Processes
Pembrolizumab
Vaccines
Immunoglobulins
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents